Gilead Sciences (GILD)
What changed in recent filings
- Revenue +10% YoYQuarter ended Jun 30, 2026
- Institutions — 4 added · 1 reduced13F · as of end of 2026 Q2
- Debt-to-equity 0.9x → 2.2xMar 31, 2026 → Jun 30, 2026
What changed in recent SEC filings — factual, not a buy/sell recommendation.
Gilead Sciences recent earnings releases
Based on SEC filings. The release date is the day the earnings filing (8-K) was accepted; for quarters where that filing was not found, the periodic report filing date is shown.
- 26Q2Released Aug 4, 2026Revenue +10.2% YoY · EPS $-8.45Released after the close: Aug 4 close → Aug 5 close, the stock moved -2.6% · over the same window, market -0.2% · sector +0.5%
- 26Q1Released May 7, 2026Revenue +4.4% YoY · EPS $1.61Released after the close: May 7 close → May 8 close, the stock moved -2.0% · over the same window, market +0.8% · sector -0.5%
- 25Q4Released Feb 10, 2026Revenue +4.7% YoY · EPS $1.74Released after the close: Feb 10 close → Feb 11 close, the stock moved +5.8% · over the same window, market +0.0% · sector +0.4%
- 25Q3Released Oct 30, 2025Revenue +3.0% YoY · EPS $2.43Released after the close: Oct 30 close → Oct 31 close, the stock moved +1.1% · over the same window, market +0.3% · sector +0.0%
The next earnings release is estimated around Oct 29, 2026 (calculated from how long this company has taken between quarter end and filing; it is not a date announced by the company).
Institutions holding Gilead Sciences
How many of the institutions we track reported holding this stock, quarter by quarter.
2019 Q1: 5 → 2026 Q2: 7 institutions
Counts the 52 institutions we track that reported holding this stock — their full reported holdings, not just the largest positions. Not the total number of institutional holders in the US. Figures are as of quarter-end and disclosed up to 45 days later. Descriptive only — not investment advice.
Which institutions hold Gilead Sciences
Institutions we track that reported holding this stock in their most recent 13F.
- National Pension Service (Korea)0.25% of portfolio · held as of 2019 Q1 or earlier
- Dodge & Cox1.57% of portfolio · held as of 2019 Q1 or earlier
- Caisse de depot (Quebec)0.38% of portfolio · held as of 2019 Q1 or earlier
- Capital World Investors0.61% of portfolio · held as of 2020 Q3 or earlier
- Bridgewater Associates0.15% of portfolio · since 2020 Q4
- Tudor Investment Corp0.01% of portfolio · since 2026 Q1
- Point72 Asset Management0.20% of portfolio · since 2026 Q1
Based on 13F filings — quarter-end holdings, disclosed up to 45 days later. Holding a stock is a fact we report, not a recommendation to buy or sell.
Q2 2026 13F recap — stocks several institutions bought and sold together →Company overview
A biopharma company generating steady cash flow from the hepatitis-C drug sofosbuvir and the HIV drug Biktarvy.
What is the Biotech & Health sector?
Pharma, biotech, and medical devices. Driven by trial-result events.
Gilead Sciences is classified under the Biotech & Health sector. See peers below.
Gilead Sciences key financials
Based on SEC filings · as of Jun 30, 2026
Tap a metric name to see its meaning in the glossary.
Gilead Sciences vs Biotech & Health sector benchmark
Median of 38 representative sector stocks · SEC filings · factual comparison (not advice)
A simple comparison to the sector benchmark. Higher or lower doesn’t mean good/bad or buy/sell.
GILD revenue by segment summary
SEC 10-Q · segment totals cross-checked against total revenue
2026-06-30 revenue was $7.8B, +10.2% YoY.
The largest segment is United States, 71.8% of revenue — a highly concentrated structure.
Recent revenue growth was led mainly by the United States segment (about 77% of the increase).
Full segment weights, YoY changes, and an AI synthesis are available in the detailed analysis.
GILD segment revenue mix trend
Quarterly change in segment revenue share · verified from SEC filings
ETFs holding Gilead Sciences
Per SEC N-PORT · 2026-06-30 · by weight · factual
GILD on Stocklore
- Revenue by segment — segment weights verified from SEC filings, YoY changes, growth drivers and concentration
- Financials & earnings quality — 6 metrics (FCF conversion, ROIC, net debt, etc.) to gauge profit quality
- 13F institutional holdings — holdings and weight changes of major institutions (45-day delay)
- Sector-relative metrics — Valuation and growth compared with the Biotech & Health average
Peers · Biotech & Health
GILD FAQ
What is Gilead Sciences (GILD)?
A biopharma company generating steady cash flow from the hepatitis-C drug sofosbuvir and the HIV drug Biktarvy.
What sector is Gilead Sciences in?
Gilead Sciences is classified under Biotech & Health. Pharma, biotech, and medical devices. Driven by trial-result events.
What are Gilead Sciences's key financials?
As of Jun 30, 2026 in SEC filings: Revenue growth (YoY) 5.5%, Operating margin -133.2%, Net margin -10.6%, ROE 37.5%, Debt-to-equity 2.22x. Definitions and interpretation are available on Stocklore.
What are Gilead Sciences's main revenue segments?
The largest segment is United States, about 71.8% of revenue. Segment totals are cross-checked against total revenue from SEC filings.
Where can I analyze Gilead Sciences (GILD) stock?
On Stocklore you can see GILD's financials & earnings quality, 13F institutional holdings, and sector-relative metrics in one place. This page is for information and tools — not a buy/sell recommendation.
Data sources: SEC EDGAR (financials & filings), 13F (institutional holdings, as of quarter-end), market data. This page is for information and analysis tools — it does not recommend buying or selling any security. Investment decisions and responsibility are your own.